FrancophonIA/ELRC3.0 huggingface dataset:
English: When Luxturna is injected into the eye the virus carries the RPE65 gene into the retinal cells and enables them to produce the missing enzyme.
Croatian: Kada se lijek Luxterna ubrizga u oko, virus prenosi gen RPE65 u stanice mrežnice i omogućuje im da proizvode enzim koji nedostaje.
English: Luxturna has been shown to improve patients' vision and ability to move around obstacles, particularly in dim light, and is expected to improve their quality of life.
Croatian: Utvrđeno je da lijek Luxturna poboljšava vid u bolesnika, kao i njihovu sposobnost kretanja oko prepreka, posebno pri prigušenom svjetlu, te se očekuje da će poboljšati kvalitetu njihova života.
English: Luxturna can only be obtained with a prescription and treatment should be given by a surgeon experienced in performing eye surgery.
Croatian: Lijek Luxturna izdaje se samo na liječnički recept, a liječenje mora započeti kirurg iskusan u izvođenju operacije oka.
English: For more information about using Luxturna, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Luxturna pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: Luxturna can only be used while patients still have enough functioning cells left in the retina and when the disease is caused by mutations (changes) in the gene RPE65.
Croatian: Lijek Luxturna smije se primjenjivati samo u bolesnika koji još uvijek imaju dovoljno funkcionalnih stanica u mrežnici te kad je bolest uzrokovana mutacijama (promjenama) u genu RPE65.
English: Luxturna consists of a virus that contains normal copies of the RPE65 gene.
Croatian: Lijek Luxturna sastoji se od virusa koji sadržava ispravne kopije gena RPE65.
English: The most common side effects with Luxturna (which may affect more than 1 in 20 people) are conjunctival hyperaemia (increased blood supply to the eye, leading to redness of the eye), cataract (clouding of the lens of the eye) and increased pressure inside the eye. For the full list of side effects of Luxturna, see the package leaflet.
Croatian: Najčešće nuspojave lijeka Luxturna (koje se mogu javiti u više od 1 na 20 osoba) jesu hiperemija konjunktive (povećani dotok krvi u oko, što uzrokuje crvenilo oka), katarakta (zamućenje leća oka) i povišeni tlak unutar oka.
English: What benefits of Luxturna have been shown in studies?
Croatian: Koje su koristi od lijeka Luxturna utvrđene u ispitivanjima?
English: Luxturna was investigated in one main study involving 31 patients with inherited retinal dystrophy due to RPE65 mutations.
Croatian: Lijek Luxturna ispitivan je u jednom glavnom ispitivanju koje je obuhvatilo 31 bolesnika s nasljednom retinalnom distrofijom uzrokovanom mutacijama gena RPE65.
English: Luxturna is given as a single injection into the back of each eye, under the retina.
Croatian: Lijek Luxturna primjenjuje se subretinalno, kao jedna injekcija u stražnji dio svakog oka.
English: How does Luxturna work?
Croatian: Kako djeluje Luxturna?
English: How is Luxturna used?
Croatian: Kako se Luxturna primjenjuje?
English: The safety of Luxturna was considered acceptable and side effects manageable.
Croatian: Smatra se da je sigurnost primjene lijeka Luxturna prihvatljiva te da se nuspojave mogu kontrolirati.
English: OTHER SPECIAL WARNING(S):
Croatian: DRUGO(A) POSEBNO(A) UPOZORENJE(A):
English: Annex III Amendments to relevant sections of the Product Information
Croatian: Prilog III Izmjene odgovarajućih dijelova informacija o lijeku
English: [This statement below should be strongly emphasised (e.g. capitalized, bold letters or use of colours), the visual details of the warning on the outer and immediate packaging should be agreed with NCAs and be subject to a user test taking into account the "Guideline on the Readability of the labelling and package leaflet on medicinal products for human use" within 1 month from the Commission Decision.]
Croatian: [Sljedeći navod treba biti jako naglašen (npr. velikim slovima, podebljano ili u boji), a vizualni detalji upozorenja na vanjskom i unutarnjem pakiranju trebaju biti dogovoreni s nacionalnim nadležnim tijelima i za njih je potrebno provesti ispitivanje razumljivosti uzimajući u obzir smjernicu "Guideline on the Readability of the labelling and package leaflet on medicinal products for human use" unutar 1 mjeseca od odluke Komisije.]
English: See situations in which this product should never be used in section 2.
Croatian: Sva stanja u kojima se ovaj lijek ne smije koristiti pogledajte u dijelu 2.
English: The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC.
Croatian: Informacije o lijeku mogu naknadno ažurirati nadležna tijela država članica, u suradnji s referentnom državom članicom, ako je prikladno, u skladu s postupcima utvrđenim u poglavlju 4. glave III.
English: MAHs of HES solution for infusion should amend the product information (insertion, replacement or deletion of the text, as appropriate) to reflect the wording as provided below, and in conjunction to the Scientific conclusions:
Croatian: Nositelji odobrenja za HES otopinu za infuziju trebaju izmijeniti informacije o lijeku (umetanjem, zamjenom ili uklanjanjem teksta, prema potrebi) kako bi sadržavale tekst naveden u nastavku, a vezano uz znanstvene zaključke:
English: These amendments to the relevant sections of the Summary of Product Characteristics and package leaflet are the outcome of the referral procedure.
Croatian: Ove izmjene odgovarajućih dijelova sažetka opisa svojstava lijeka i upute o lijeku rezultat su ishoda arbitražne procedure.
English: SEE ALL CONTRAINDICATIONS IN THE SMPC.
Croatian: ZA SVE KONTRAINDIKACIJE POGLEDAJTE SAŽETAK OPISA SVOJSTAVA LIJEKA.
English: Warning Do not use in sepsis (severe generalised infection), renal impairment, or critically ill patients.
Croatian: Ne smije se koristiti kod sepse (ozbiljne generalizirane infekcije), oštećenja bubrega ili u bolesnika u kritičnom stanju.
English: Contraindications Do not use in sepsis, renal impairment, or critically ill patients.
Croatian: NE SMIJE SE KORISTITI KOD SEPSE, OŠTEĆENJA BUBREGA ILI U BOLESNIKA
English: SUMMARY OF PRODUCT CHARACTERISTICS [This statement below should be added in a black box at the top of the SmPC.]
Croatian: SAŽETAK OPISA SVOJSTAVA LIJEKA [Sljedeći navod treba dodati u crnom okviru na vrhu sažetka opisa svojstava lijeka.] Kontraindikacije Ne smije se koristiti kod sepse, oštećenja bubrega ili u bolesnika u kritičnom stanju.
English: The duration of treatment depends on the patient's condition.
Croatian: Trajanje terapije ovisi o stanju bolesnika.
English: The duration of treatment depends on the severity of the disease and the patient's response.
Croatian: Trajanje liječenja ovisi o ozbiljnosti bolesti i reakciji bolesnika.
English: Without ergosterol, the fungus dies or is prevented from spreading.
Croatian: Gljivica bez ergosterola umire ili je onemogućeno njezino širenje.
English: Further information on Poxaconazole AHCL can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/posaconazole-ahcl.
Croatian: Više informacija o lijeku Posaconazole AHCL dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/posaconazole-ahcl.
English: It works by preventing the formation of ergosterol, which is an important part of fungal cell walls.
Croatian: Djeluje sprječavanjem formiranja ergosterola, važnog sastavnog dijela stijenke gljivične stanice.
English: • chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters),
Croatian: • kromoblastomikoze i micetoma (dugotrajnih gljivičnih infekcija kože ili tkiva neposredno pod kožom, koje obično uzrokuju gljivične spore inficiranjem rana od trnja ili krhotina),
English: Posaconazole AHCL is available as an oral suspension (40 mg/ml) which is taken with a meal or nutritional supplement.
Croatian: Posaconazole AHCL dostupan je kao oralna suspenzija (40 mg/ml) koja se uzima uz obrok ili kao dodatak prehrani.
English: It is used in patients whose infection is severe or in patients with weakened immune systems, when medicines applied topically (directly on the thrush) are unlikely to work.
Croatian: Primjenjuje se u bolesnika s ozbiljnim infekcijama ili u onih s oslabljenim imunitetom kada nije vjerojatno da će lijekovi primijenjeni izravno na infekciju (mliječac) djelovati.
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Noxafil, and do not need to be repeated for Posaconazole AHCL.
Croatian: Ispitivanja koristi i rizika djelatne tvari u odobrenim primjenama već su provedena s referentnim lijekom Noxafil i stoga ih nije potrebno ponavljati za lijek Posaconazole AHCL.
English: Side effects reported with Posaconazole AHCL are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Posaconazole AHCL pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Posaconazole AHCL is an antifungal medicine used to treat adults with the following fungal diseases, when treatments with other antifungal medicines (amphotericin B, itraconazole or fluconazole) cannot be tolerated or have failed:
Croatian: Posaconazole AHCL je lijek protiv gljivica za liječenje odraslih s gljivičnim oboljenjima u nastavku kada bolesnik terapiju drugim lijekovima protiv gljivica (kao što su amfotericin B, itrakonazol ili flukonazol) ne može podnijeti ili ona nije bila učinkovita:
English: This means that Posaconazole AHCL contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Noxafil.
Croatian: To znači da Posaconazole AHCL sadrži istu djelatnu tvar i djeluje na jednak način kao i „referentni lijek” koji je već odobren u EUu pod nazivom Noxafil.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Posaconazole AHCL has been shown to have comparable quality and to be bioequivalent to Noxafil.
Croatian: Europska agencija za lijekove zaključila je kako je, u skladu sa zahtjevima EU-a, utvrđeno da lijek Posaconazole AHCL ima usporedivu kakvoću te da je bioekvivalentan lijeku Noxafil.
English: Posaconazole AHCL is also used to prevent invasive fungal infections in patients whose immune system is weakened because of treatments they are receiving for blood or bone marrow cancers or medicines used in haematopoietic stem cell transplantation (a procedure where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow).
Croatian: Posaconazole AHCL također se primjenjuje za suzbijanje invazivnih gljivičnih infekcija u bolesnika s oslabljenim imunitetom zbog terapija koje primaju protiv raka krvi ili koštane srži ili lijekova koji se primjenjuju u transplantaciji hematopoetskih matičnih stanica (postupku u kojem se koštana srž bolesnika zamjenjuje matičnim stanicama donatora s ciljem stvaranja nove koštane srži).
English: Because Posaconazole AHCL is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Posaconazole AHCL generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: Posaconazole AHCL can only be obtained with a prescription and treatment should be started by a doctor who has experience in managing fungal infections or in treating patients at high risk of invasive fungal infections.
Croatian: Posaconazole AHCL izdaje se samo na liječnički recept, a liječenje treba započeti liječnik s iskustvom u liječenju gljivičnih infekcija ili bolesnika kod kojih postoji velik rizik od invazivnih gljivičnih infekcija.
English: Posaconazole AHCL is also used as a first-line treatment for ‘thrush', a fungal infection of the mouth and throat due to Candida.
Croatian: Posaconazole AHCL također se primjenjuje kao prva linija terapije za „mliječac”, gljivičnu infekciju usta i grla koju uzrokuje Candida.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Posaconazole AHCL have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Posaconazole AHCL nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: Posaconazole AHCL (posaconazole)
Croatian: Posaconazole AHCL (posakonazol)
English: What measures are being taken to ensure the safe and effective use of Posaconazole AHCL?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Posaconazole AHCL?
English: For the prevention of invasive fungal infections, Posaconazole AHCL is taken at a dose of 200 mg (5 ml) three times a day.
Croatian: Za suzbijanje invazivnih gljivičnih infekcija, Posaconazole AHCL uzima se u dozi od 200 mg (5 ml) tri puta dnevno.
English: An overview of Posaconazole AHCL and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Posaconazole AHCL i zašto je odobren u EU-u
English: For the treatment of fungal infections, with the exception of thrush, Posaconazole AHCL is taken at a dose of 400 mg (10 ml) twice a day, or 200 mg (5 ml) four times a day in patients who are not eating.
Croatian: Za liječenje gljivičnih infekcija, osim za mliječac, Posaconazole AHCL se uzima u dozi od 400 mg (10 ml) dva puta dnevno, ili 200 mg (5 ml) četiri puta dnevno kod bolesnika koji ne jedu.
English: The active substance in Posaconazole AHCL, posaconazole, is an antifungal medicine that belongs to the triazole group.
Croatian: Djelatna tvar u lijeku Posaconazole AHCL, posakonazol, lijek je protiv gljivica iz skupine triazola.
English: Why is Posaconazole AHCL authorised in the EU?
Croatian: Zašto je Posaconazole AHCL odobren u EU-u?
English: For more information about using Posaconazole AHCL, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Posaconazole AHCL pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: For thrush, Posaconazole AHCL is taken as 200 mg (5 ml) on the first day followed by 100 mg (2.5 ml) once a day for the following 13 days.
Croatian: Za mliječac se Posaconazole AHCL uzima u dozi od 200 mg (5 ml) prvog dana, a zatim od 100 mg (2,5 ml) jednom dnevno tijekom 13 dana.
English: Therefore, the Agency's view was that, as for Noxafil, the benefit of Posaconazole AHCL outweighs the identified risk and it can be authorised for use in the EU.
Croatian: Stoga je stav Agencije da korist od lijeka Posaconazole AHCL, kao i od lijeka Noxafil, nadmašuje identificirani rizik te da lijek može biti odobren za primjenu u EU-u.
English: Posaconazole AHCL contains the active substance posaconazole and is a ‘generic medicine'.
Croatian: Posaconazole AHCL sadrži djelatnu tvar posakonazol te je „generički lijek”.
English: Other information about Posaconazole AHCL
Croatian: Ostale informacije o lijeku Posaconazole AHCL
English: As for every medicine, the company provided studies on the quality of Posaconazole AHCL.
Croatian: Kao i za svaki lijek, tvrtka je dostavila podatke o ispitivanjima kakvoće lijeka Posaconazole AHCL.
English: What are the benefits and risks of Posaconazole AHCL?
Croatian: Koje su koristi i rizici od lijeka Posaconazole AHCL?
English: What is Posaconazole AHCL and what is it used for?
Croatian: Što je Posaconazole AHCL i za što se koristi?
English: As for all medicines, data on the use of Posaconazole AHCL are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Posaconazole AHCL kontinuirano se prate.
English: How does Posaconazole AHCL work?
Croatian: Kako djeluje Posaconazole AHCL?
English: The list of fungi posaconazole is active against can be found in the summary of product characteristics.
Croatian: Popis gljivica protiv kojih posakonazol djeluje nalazi se u sažetku opisa svojstava lijeka.
English: How has Posaconazole AHCL been studied?
Croatian: Kako je Posaconazole AHCL ispitivan?
English: Posaconazole AHCL received a marketing authorisation valid throughout the EU on 25 July 2019.
Croatian: Posaconazole AHCL (posakonazol) EMA/323099/2019
English: Otto Hahnweg 24 3542 AX Utrecht NETHERLANDS
Croatian: Otto Hahnweg 24 3542 AX Utrecht NIZOZEMSKA
English: Treatment can be continued for a maximum of 14 consecutive days.
Croatian: Liječenje se može nastaviti tijekom maksimalno 14 uzastopnih dana.
English: Horse.
Croatian: Konji.
English: Date of last renewal: 13 November 2007
Croatian: Datum zadnjeg odobrenja: 13. studenog 2007.
English: Twice daily administration.
Croatian: Primjenjuje se dvaput dnevno.
English: It is advisable to administer the product before feeding.
Croatian: Savjetuje se proizvod primijeniti prije davanja hrane.
English: The terminal half-life following oral administration is 350-500 minutes and no accumulation occurs following repeated oral dosing.
Croatian: Terminalni poluvijek nakon oralne primjene je 350-500 minuta i ne dolazi do nakupljanja nakon ponovljenog oralnog doziranja.
English: Bioavailability after oral administration is 80-90%, but is reduced significantly if medication is administered with food.
Croatian: Bioraspoloživost nakon oralne primjene je 80-90 %, ali značajno se smanjuje ako se lijek primijeni s hranom.
English: Do not use in foals under the age of 6 months.
Croatian: Ne smije se primjenjivati ždrebadi mlađoj od 6 mjeseci.
English: In case of doubt, it is advisable to test the urine.
Croatian: Ako niste sigurni, savjetuje se testirati urin.
English: Approximately 70% of an orally administered dose is excreted in the urine.
Croatian: Približno 70 % oralno primijenjene doze izlučuje se kroz urin.
English: Overdosing may lead to death of treated animals.
Croatian: Predoziranje može uzrokovati smrt liječenih životinja.
English: The product is presented as a single syringe in a carton box or as a multipack of 3 syringes in a carton box.
Croatian: Proizvod je pakiran u obliku pojedinačne štrcaljke u kartonskoj kutiji ili kao višestruko pakiranje s 3 štrcaljke u kartonskoj kutiji.
English: The most abundant metabolite is a monohydroxylated derivative.
Croatian: Najobilniji metabolit je monohidroksilirani derivat.
English: In case of prophylactic treatment, a maximum duration of treatment of 7 consecutive days is sufficient.
Croatian: U slučaju profilaktičkog liječenja dovoljno je maksimalno trajanje od 7 uzastopnih dana.
English: Meat and offal: 12 days Not authorised for use in animals producing milk for human consumption.
Croatian: Meso i iznutrice: 12 dana Nije odobrena primjena na životinjama koje proizvode mlijeko za ljudsku upotrebu.
English: Quadrisol 100 mg/ml can be used during pregnancy.
Croatian: Quadrisol 100 mg/ml može se primjenjivati tijekom graviditeta.
English: Horses intended for racing and competition should be treated according to local requirements.
Croatian: Konje namijenjene za utrke i natjecanja treba liječiti u skladu s lokalnim propisima.
English: Symptoms are reversible.
Croatian: Simptomi su reverzibilni.
English: The active substance in Quadrisol is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Croatian: Djelatna tvar u lijeku Quadrisol je dozvoljena tvar kako je je navedeno u tablici 1, Dodatka Uredbe Komisije (EU) br. 37/2010:
English: Not authorised for use in lactating animals producing milk for human consumption.
Croatian: Nije odobrena primjena na životinjama koje proizvode mlijeko za ljudsku upotrebu.
English: Horses with oral lesions should be assessed clinically and the attending veterinarian should take a decision as to whether treatment should be continued.
Croatian: Konje s oralnim lezijama treba klinički procijeniti, a nadležni veterinar treba odlučiti o tome treba li prekinuti liječenje.
English: Appropriate precautions must be taken for such horses to ensure compliance with competition regulations.
Croatian: Kod takvih konja treba poduzeti odgovarajuće mjere opreza da bi se osigurala usklađenost s propisima natjecanja.
English: Both enantiomers are equipotent PGF2α antagonists.
Croatian: Oba su enantiomera jednako snažni antagonisti PGF2α.
English: Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as there may be potential risk of increased renal toxicity.
Croatian: Izbjegavajte primjenu na dehidriranim, hipovolemičnim ili hipotenzivnim životinjama jer može postojati rizik od povećane renalne toksičnosti.
English: Other NSAIDs, diuretics and substances with high protein binding may compete for binding and lead to toxic effects.
Croatian: Ostali NSAIL-i, diuretici i tvari s visokim vezanjem na proteine mogu konkurirati u vezanju te tako uzrokovati toksične učinke.
English: Studies in the horse have demonstrated potent inhibition of prostaglandin E2 (PG E2) synthesis in exudate and thromboxane B2 synthesis in serum and exudate.
Croatian: Ispitivanja na konjima dokazala su snažnu inhibiciju sinteze prostaglandina E2 (PG E2) u eksudatu i sintezu tromboksana B2 u serumu i eksudatu.
English: For oral use.
Croatian: Za oralnu primjenu.
English: Vedaprofen contains an asymmetric carbon atom and, therefore, is a racemic mixture of a (+) enantiomer and a (-) enantiomer.
Croatian: Vedaprofen sadrži asimetrični atom ugljika i stoga racemičnu smjesu (+) enantiomera i (-) enantiomera.
English: Reduction of inflammation and relief of pain associated with musculo-skeletal disorders and soft tissue lesions (traumatic injuries and surgical trauma).
Croatian: Smanjenje upale i ublaženje boli povezane s mišićno-koštanim poremećajima i lezijama mekog tkiva (traumatskim ozljedama i kirurškim traumama).
English: EXPIRY DATE EXP: {Month/year}
Croatian: EXP: {mjesec/godina}
English: The gel is administered orally by inserting the nozzle of the syringe through the interdental space and depositing the required amount of gel on the back of the tongue.
Croatian: Gel se primjenjuje oralno tako da se mlaznica štrcaljke umetne kroz interdentalni prostor, a potrebna količina gela istisne na stražnji dio jezika.
English: EU/2/97/005/005
Croatian: EU/2/97/005/001 EU/2/97/005/005
English: PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: non-steroidal anti-inflammatory drug ATCvet code: QM01AE90
Croatian: Farmakoterapijska skupina: nesteroidni protuupalni (antiinflamatorni) lijek ATCvet kod: QM01AE90
English: Meat and offal: 12 days.
Croatian: Meso i iznutrice: 12 dana.
English: Quadrisol must not be given with other NSAIDs or glucocorticosteroids.
Croatian: Quadrisol se ne smije davati zajedno s drugim NSAIL-ima ili glukokortikosteroidima.
English: Water (minimum purified grade), Propylene glycol, Hydroxyethylcellulose, Potassium hydroxide (E525), Hydrochloric acid, Chocolate flavour.
Croatian: Voda (minimalni stupanj pročišćenosti), propilenglikol, hidroksietilceluloza, kalijev hidroksid (E525), klorovodična kiselina, aroma čokolade.
English: Before administration, the syringe should be adjusted to the calculated dosage by setting the ring on the plunger.
Croatian: Prije primjene štrcaljku treba prilagoditi izračunatoj dozi tako da se postavi prsten na klipu.
English: The syringe is fitted with variable dose capability, adjustable in steps of 0.5 ml and graduated to 1 ml.
Croatian: Štrcaljka ima mogućnost varijabilnih doza, podesiva je u koracima od 0,5 ml i graduirana na 1 ml.
English: Vedaprofen is highly bound to plasma proteins and extensively metabolised.
Croatian: Vedaprofen se u visokoj mjeri veže na proteine u plazmi i ekstenzivno metabolizira.
English: Adjustable dose syringe, containing 30 ml gel 3 adjustable dose syringes, each containing 30 ml gel
Croatian: Štrcaljka s prilagodljivom dozom koja sadrži 30 ml gela 3 štrcaljke s prilagodljivom dozom, svaka sadrži 30 ml gela